A study of LL-37 for the treatmemt of venous leg ulcers

Trial Profile

A study of LL-37 for the treatmemt of venous leg ulcers

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2018

At a glance

  • Drugs LL 37 (Primary)
  • Indications Leg ulcer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jul 2018 According to a ProMore Pharma media release, the Swedish Medical Products Agency has approved the companys application to start a Phase IIb study with LL-37 for treatment of venous leg ulcers (HEAL).
    • 31 Oct 2017 According to a ProMore Pharma media release, has signed an agreement with CRO PCG Clinical Services regarding management of this trial and planning to provide initial efficacy data in the second half of 2019.
    • 21 Sep 2017 According to a ProMore Pharma media release, the trial will be conducted in Europe with a planned start for patient enrolment in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top